留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

新型冠状病毒肺炎与甲状腺疾病

陈紫晗 李乃适 连小兰

陈紫晗, 李乃适, 连小兰. 新型冠状病毒肺炎与甲状腺疾病[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2021-0791
引用本文: 陈紫晗, 李乃适, 连小兰. 新型冠状病毒肺炎与甲状腺疾病[J]. 协和医学杂志. doi: 10.12290/xhyxzz.2021-0791
CHEN Zihan, LI Naishi, LIAN Xiaolan. Coronavirus Disease 2019 and Thyroid Diseases[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2021-0791
Citation: CHEN Zihan, LI Naishi, LIAN Xiaolan. Coronavirus Disease 2019 and Thyroid Diseases[J]. Medical Journal of Peking Union Medical College Hospital. doi: 10.12290/xhyxzz.2021-0791

新型冠状病毒肺炎与甲状腺疾病

doi: 10.12290/xhyxzz.2021-0791
详细信息
    通讯作者:

    李乃适,E-mail:lns@medmail.com.cn

  • 中图分类号: R581

Coronavirus Disease 2019 and Thyroid Diseases

  • 摘要: 新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)疫情发生以来出现了若干COVID-19相关甲状腺疾患的报道,包括亚急性甲状腺炎、自身免疫性甲状腺疾病、非甲状腺疾病综合征以及一些原因未明的甲状腺功能异常。本综述旨在总结COVID-19相关甲状腺疾患的临床特点,并初步讨论其可能的作用机制。
  • [1] Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China:a single-centered, retrospective, observational study[J]. The Lancet Respiratory Medicine, 2020, 8:475-481.
    [2] Ge H, Wang X, Yuan X, et al. The epidemiology and clinical information about COVID-19[J]. Eur J Clin Microbiol Infect Dis, 2020, 39:1011-1019.
    [3] Doustmohammadian S, Doustmohammadian A, Momeni M. Association between thyroid disorders and COVID-19:a protocol for a systematic review and meta-analysis[J]. Thyroid Res, 2021, 14:21.
    [4] Pearce EN, Farwell AP, Braverman LE. Thyroiditis[J]. N Engl J Med, 2003, 348:2646-2655.
    [5] Desailloud R, Hober D. Viruses and thyroiditis:an update[J]. Virol J, 2009, 6:5.
    [6] Brancatella A, Ricci D, Viola N, et al. Subacute Thyroiditis After Sars-COV-2 Infection[J]. J Clin Endocrinol Metab, 2020, 105.
    [7] Caron P. Thyroiditis and SARS-CoV-2 pandemic:a review[J]. Endocrine, 2021, 72(2):326-331.
    [8] Inaba H, Aizawa T. Coronavirus Disease 2019 and the Thyroid-Progress and Perspectives[J]. Frontiers in Endocrinology, 2021, 12:708333.
    [9] Ippolito S, Dentali F, Tanda ML. SARS-CoV-2:a potential trigger for subacute thyroiditis?Insights from a case report[J]. J Endocrinol Invest, 2020, 43:1171-1172.
    [10] Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19[J]. Nat Rev Rheumatol, 2020, 16(8):413-414.
    [11] Testa A, Castaldi P, Fant V, et al. Prevalence of HCV Antibodies in Autoimmune Thyroid Disease[J]. Eur Rev Med Pharmacol Sci, 2006, 10:183-186.
    [12] Sultanova A, Cistjakovs M, Gravelsina S, et al. Association of Active Human Herpesvirus-6(HHV-6) Infection With Autoimmune Thyroid Gland Diseases[J]. Clin Microbiol Infect, 2017, 23:50 e51-50 e55.
    [13] Harris A, Al Mushref M. Graves'Thyrotoxicosis Following SARS-CoV-2 Infection[J]. AACE Clin Case Rep, 2021, 7:14-16.
    [14] Jiménez-Blanco S, Pla-Peris B, Marazuela M. COVID-19:a cause of recurrent Graves'hyperthyroidism?[J]. J Endocrinol Invest, 2021, 44:387-388.
    [15] Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease:report of two cases of Graves'disease after COVID-19[J]. J Endocrinol Invest, 2020, 43:1527-1528.
    [16] Tee LY, Hajanto S, Rosario BH. Covid-19 Complicated by Hashimoto's Thyroiditis[J]. Singapore Med J, 2021, 62:265.
    [17] Fliers E, Boelen A. An update on non-thyroidal illness syndrome[J]. J Endocrinol Invest, 2021, 44:1597-1607.
    [18] Zou R, Wu C, Zhang S, et al. Euthyroid Sick Syndrome in Patients With COVID-19[J]. Front Endocrinol (Lausanne), 2020, 11:566439.
    [19] Khoo B, Tan T, Clarke SA, et al. Thyroid Function Before, During, and After COVID-19[J]. J Clin Endocrinol Metab, 2021, 106:e803-e811.
    [20] Gao W, Guo W, Guo Y, et al. Thyroid hormone concentrations in severely or critically ill patients with COVID-19[J]. J Endocrinol Invest, 2021, 44:1031-1040.
    [21] Shabana TS, Anis SG, Ibrahim DM. Association between Thyroid Dysfunction and Intensive Care Unit-Acquired Weakness:A Case-Control Study[J]. Crit Care Res Pract, 2021, 2021:8889036.
    [22] Wang W, Su X, Ding Y, et al. Thyroid function abnormalities in COVID-19 patients[J]. Front Endocrinol (Lausanne), 2020, 11:623792.
    [23] Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with COVID-19:a retrospective study[J]. Thyroid, 2020, 31:8-11.
    [24] Lania A, Sandri MT, Cellini M, et al. Thyrotoxicosis in patients with Covid-19:the Thyrcov study[J]. Eur J Endocrinol, 2020, 183:381-387.
    [25] Campi I, Bulgarelli I, Dubini A, et al. The spectrum of thyroid
function tests during hospitalization for SARS COV-2 infection[J].Eur J Endocrinol, 2021, 184:699-709.
    [26] Güven M, Gültekin H. The prognostic impact of thyroid disorders on the clinical severity of COVID-19:results of single-centre pandemic hospital[J]. Int J Clin Pract, 2021, 75:e14129.
    [27] Daraei M, Hasibi M, Abdollahi H, et al. Possible role of hypothyroidism in the prognosis of COVID-19[J]. Intern Med J, 2020, 50:1410-1412.
    [28] Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis[J]. The Lancet Diabetes&Endocrinology, 2020, 8:739-741.
    [29] Lam SD, Bordin N, Waman VP, et al. SARS-CoV-2 spike protein predicted to form complexes with host receptor protein orthologues from a broad range of mammals[J]. Sci Rep, 2020, 10:16471.
    [30] Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues[J]. Infect Dis Poverty, 2020, 9:45.
    [31] Rotondi M, Coperchini F, Ricci G, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells:a clue for COVID-19-related subacute thyroiditis[J]. J Endocrinol Invest, 2021, 44:1085-1090.
    [32] Moore JB, June CH. Cytokine release syndrome in severe Covid-19[J]. Science, 2020, 368:473-474.
    [33] Turner AJ, Tipnis SR, Guy Jl, et al. Aceh/Ace2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ace inhibitors[J]. Can J Physiol Pharmacol, 2002, 80:346-353.
    [34] Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2[J]. Antiviral Res, 2020, 177:104759.
    [35] Luan J, Lu Y, Gao S, et al. A potential inhibitory role
for integrin in the receptor targeting of SARS-CoV-2[J]. J Infect, 2020, 81:318-356.
    [36] Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+and CD8+T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19[J]. Nat Immunol, 2020, 21:1336-1345.
    [37] Coomes EA, Haghbayan H. Interleukin-6 in Covid-19:A systematic review and meta-analysis[J]. Rev Med Virol, 2020, 30:1-9.
    [38] Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19[J]. Nature, 2020, 583:437-440.
    [39] Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19[J]. Sci Immunol, 2020, 5:eabd1554.
    [40] Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19[J]. Nature, 2020, 584:463-469.
    [41] Melo Silva Junior ML, Souza LMA, Dutra R, et al. Review on therapeutic targets for COVID-19:insights from cytokine storm[J]. Postgrad Med J, 2021, 97:391-398.
    [42] Caron P. Thyroid disorders and SARS-CoV-2 infection:from pathophysiological mechanism to patient management[J]. Ann Endocrinol (Paris), 2020, 81:507-510.
    [43] Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves'disease[J]. Immunol Res, 2012, 54:191-203.
    [44] Kawashima A, Yamazaki K, Hara T, et al. Demonstration of innate immune responses in the thyroid gland:potential to sense danger and a possible trigger for autoimmune reactions[J]. Thyroid, 2013, 23:477-487.
    [45] Hariyanto TI, Kurniawan A. Thyroid disease is associated with severe coronavirus disease 2019(COVID-19) infection[J]. Diabetes Metab Syndr, 2020, 14:1429-1430.
    [46] Lisco G, De Tullio A, Jirillo E, et al. Thyroid and COVID-19:a review on pathophysiological, clinical and organizational aspects[J]. J Endocrinol Invest, 2021, 44:1801-1814.
  • 加载中
计量
  • 文章访问数:  71
  • HTML全文浏览量:  4
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-12-15
  • 录用日期:  2021-12-27
  • 网络出版日期:  2022-01-14

目录

    /

    返回文章
    返回